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Brain natriuretic peptide constitutively 
downregulates P2X3 receptors by controlling 
their phosphorylation state and membrane 
localization
Anna Marchenkova1†, Sandra Vilotti1†, Elsa Fabbretti2 and Andrea Nistri1*
Abstract 
Background: ATP-gated P2X3 receptors are important transducers of nociceptive stimuli and are almost exclusively 
expressed by sensory ganglion neurons. In mouse trigeminal ganglion (TG), P2X3 receptor function is unexpectedly 
enhanced by pharmacological block of natriuretic peptide receptor-A (NPR-A), outlining a potential inhibitory role of 
endogenous natriuretic peptides in nociception mediated by P2X3 receptors. Lack of change in P2X3 protein expres-
sion indicates a complex modulation whose mechanisms for downregulating P2X3 receptor function remain unclear.
Results: To clarify this process in mouse TG cultures, we suppressed NPR-A signaling with either siRNA of the endog-
enous agonist BNP, or the NPR-A blocker anantin. Thus, we investigated changes in P2X3 receptor distribution in the 
lipid raft membrane compartment, their phosphorylation state, as well as their function with patch clamping. Delayed 
onset of P2X3 desensitization was one mechanism for the anantin-induced enhancement of P2X3 activity. Anantin 
application caused preferential P2X3 receptor redistribution to the lipid raft compartment and decreased P2X3 serine 
phosphorylation, two phenomena that were not interdependent. An inhibitor of cGMP-dependent protein kinase 
and siRNA-mediated knockdown of BNP mimicked the effect of anantin.
Conclusions: We demonstrated that in mouse trigeminal neurons endogenous BNP acts on NPR-A receptors to 
determine constitutive depression of P2X3 receptor function. Tonic inhibition of P2X3 receptor activity by BNP/NPR-A/
PKG pathways occurs via two distinct mechanisms: P2X3 serine phosphorylation and receptor redistribution to non-
raft membrane compartments. This novel mechanism of receptor control might be a target for future studies aiming 
at decreasing dysregulated P2X3 receptor activity in chronic pain.
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Background
P2X3 receptors are trimeric cation channels gated by 
extracellular ATP, almost exclusively expressed by the 
majority of sensory ganglion neurons [1, 2], and impor-
tant transducers of nociceptive stimuli [3, 4]. Even 
though the P2X3 receptor desensitizes rapidly (and, 
thus, self-limits its function), it can elicit fast, strong sen-
sory neuron depolarization and firing which are actu-
ally enhanced in pathological pain states [4–8]. Certain 
endogenous modulators can upregulate P2X3 channels 
via multiple signaling pathways that alter their rate of 
synthesis, trafficking [9–11], phosphorylation state [10, 
12–15], and receptor desensitization [10, 15, 16]. In par-
ticular, a major role is played by the neuropeptide cal-
citonin gene-related peptide (CGRP) that persistently 
enhances P2X3 receptor activity and, thereby, contrib-
utes to the development of algogenic syndromes in 
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inflammation [17–19], chronic and neuropathic pain [10, 
20], and migraine headache [21, 22]. It is, however, con-
ceivable that endogenous substances may serve as nega-
tive regulators of P2X3 receptors under basal conditions. 
Their dysfunction might actually contribute to pain sen-
sitization, a notion that could potentially paved the way 
to design novel analgesic drugs.
One candidate for the role of endogenous negative 
regulator of sensory ganglion activity is the brain natriu-
retic peptide (BNP). In fact, BNP downregulates inflam-
matory pain as well as firing frequency of small neurons 
in dorsal root ganglia (DRG; [9, 23]). BNP is one of the 
three structurally related paracrine factors belong-
ing to natriuretic peptides family [24]. This peptide is a 
potent agonist on NPR-A receptors [24, 25] abundantly 
expressed by DRG CGRP-containing neurons [9] and 
trigeminal ganglion (TG) neurons [26] in which BNP-
dependent NPR-A activation increases cGMP produc-
tion [26, 27]. It is suggested that this system plays a 
constitutive inhibitory role in nociception mediated 
by P2X3 receptors because sustained pharmacological 
block of NPR-A strongly enhances P2X3 receptor medi-
ated responses [26].
The molecular mechanism underlying the NPR-A 
dependent inhibition of TG P2X3 receptor function 
remains unclear. Our previous data indicate that NPR-A 
antagonism does not interfere with P2X3 expression [26], 
outlining a subtle process of P2X3 modulation. Potential 
targets might be the fine balance between phosphoryla-
tion and dephosphorylation controlling channel struc-
ture and function [3, 10, 13, 14, 28] or the differential 
distribution of P2X3 receptor between cholesterol-rich 
raft and non-raft membrane compartments [29–32].
The aims of the present study were to clarify the mech-
anisms and dynamics of BNP mediated constitutive regu-
lation of P2X3 receptor function. Thus, we investigated 
changes in P2X3 receptor compartmentalization and 
phosphorylation state, and the role of certain intermedi-
ate steps in this process. To this end, BNP siRNA or the 
selective NPR-A blocker anantin were used to suppress 
NPR-A signaling and to evaluate any alteration in P2X3 
receptor membrane distribution and phosphorylation 
state. Our results indicated multiple processes through 
which BNP-dependent NPR-A activity controlled P2X3 
receptors.
Results
Unmasking tonic inhibition of P2X3 receptors by BNP
To support constitutive inhibition of P2X3 receptor 
activity by endogenous BNP in mouse TG neurons, the 
present study looked for changes in P2X3 receptor func-
tion after siRNA of BNP and compared this effect with 
the action of the pharmacological antagonist anantin.
Following BNP siRNA (48 h), no BNP (measured with 
the standard ELISA assay) could be detected in the cul-
ture medium, while in control conditions BNP was clearly 
detectable (4.7 ± 1.5 ng/ml), consistent with our previous 
report [26]. Furthermore, even if immunoreactive cells 
for BNP are just a few in cultured or in  situ trigeminal 
ganglia ([26]; see top panels in Fig. 1a), after 48 h siRNA 
immunohistochemical staining did not demonstrate any 
BNP immunopositive cells in TG culture (Fig.  1a, bot-
tom panels). P2X3 receptor mediated currents elicited 
by the selective P2X3 agonist α,β-methylene-ATP (α,β-
meATP) [33] were next investigated using trigeminal sen-
sory neurons (see experimental protocols schematized in 
Fig. 1b, bottom panels). Thus, BNP siRNA yielded larger 
amplitude responses that were similar to those recorded 
after anantin application (as exemplified in the records 
of Fig. 1b, left). When anantin was applied over a back-
ground of siRNA BNP, no further upregulation of P2X3 
receptor function was observed, as seen from the histo-
grams (Fig.  1b, right) and representative current traces 
(Fig. 1b, left). In addition, after siRNA BNP, 2 h applica-
tion of BNP (100 mg/ml) depressed P2X3 receptor cur-
rents back to the untreated control level (Fig. 1b, right). 
These data, thus, validate that sustained block of NPR-A 
receptors with anantin and suppression of endogenous 
BNP synthesis evoked similar potentiation of P2X3 
receptor activity. It is also noteworthy that a significant 
decrease in P2X3 receptor function was observed with 
BNP after siRNA, unmasking an inhibitory effect of this 
peptide that had not been previously detected.
Dynamic modulation of P2X3 receptor function by the 
NPR‑A blocker anantin
We next explored the timecourse of anantin potentia-
tion of P2X3 activity, as this approach can cast light on 
the dynamics of the NPR-A modulatory action. Figure 2a 
shows examples of α,β-meATP (10  µM, 2  s)-induced 
P2X3 currents (Fig.  2a, upper panel) along with their 
mean current density values at various times of anan-
tin treatment (Fig. 2a, lower panel). In fact, a significant 
increase in P2X3 currents was observed after 1 h of anan-
tin (500  nM) application and remained at a stable pla-
teau for longer (up to 24  h) exposures. Dose–response 
curves for α,β-meATP mediated currents in control 
and after 24  h exposure to 500  nM anantin were previ-
ously described [26], showing that this potentiation 
occurred throughout the agonist concentration range. 
Anantin (500  nM, 3  h) did not change cell input resist-
ance (820 ± 57 MΩ in control versus 811 ± 58 MΩ after 
anantin treatment) or the baseline current (36 ± 5.7 pA 
in control versus 41 ±  9.1 pA after anantin treatment), 
indicating that anantin caused no significant change in 
background conductances that might have accounted 
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for a broad, non-selective rise in neuronal membrane 
responses. We also studied whether the effect of anan-
tin was reversible on washout: Fig. 2b illustrates that 5 h 
wash with standard physiological solution restored P2X3 
current values to control level.
Because desensitization is an important process to 
limit P2X3 receptor-mediated responses [10, 15, 33], we 
investigated if anantin might have impaired P2X3 desen-
sitization. Figure  2c, (left panel) shows averaged P2X3 
currents (scaled and superimposed to aid comparison) 
in control solution or after anantin application (1  h). 
P2X3 currents normally decay with a bi-exponential time 
course [33], corresponding to the fast and slow compo-
nents of P2X3 desensitization (τ1 and τ2; see also Fig. 2c, 
left) [34]. A total number of 161 currents was analyzed 
(85 in control and 76 after anantin application collected 
from several separate experiments) with peak ampli-
tudes varying from 250 to 800 pA. Figure  2c shows a 
small, albeit significant, increase in τ1 values after anantin 
application compared to the control without statistically 
significant alteration in τ2 values (Fig. 2c, right; p < 0.05, 
Mann–Whitney rank sum test). Thus, retarding the onset 
of desensitization appeared to be one mechanism for the 
anantin-induced enhancement of P2X3 activity.
Changes in extracellular CGRP do not affect anantin 
mediated P2X3 upregulation
CGRP is a powerful positive regulator of P2X3 function 
via complex signaling involving neurons and non-neu-
ronal cells [28, 35–38]. We wondered if anantin might 
act by facilitating the action of ambient CGRP in trigemi-
nal cultures [38]. Pretreatment with the selective CGRP 
receptor antagonist peptide CGRP 8-37 (1 µM, overnight; 
see the protocol scheme in Fig. 3a, right) per se did not 
modify P2X3 activity in accordance with our previous 
data [39] (Fig.  3a, left). Anantin retained its enhancing 
action on P2X3 currents even after CGRP 8-37 pretreat-
ment (Fig. 3a, left).
We also studied whether the effects of CGRP and anan-
tin were additive in upregulating P2X3 receptor currents. 
To address this issue, on the basis that the effect of anan-
tin was manifested already at 1 h (Fig. 2a), we first applied 
this antagonist (500 nM) for 1 h and then together with 
CGRP (1 µM) for further 2 h when the action of CGRP 
is known to be reliably expressed [9]. With this protocol 
(Fig. 3b, right), the increase in P2X3 activity was the same 
as with either agent applied in isolation (histogram in 
Fig. 3b, left), indicating lack of additivity.
Anantin promotes P2X3 localization to lipid rafts
In previous experiments we observed how the differ-
ential localization of P2X3 receptors to lipid raft and 
non-raft membrane compartments of sensory neurons 
is an important process to characterize the efficiency 
of P2X3 signaling [29, 31, 32, 34]. Thus, using anantin 
we tested if the P2X3 receptor membrane distribution 
was dependent on the BNP/NPR-A system. In accord-
ance with our former report [34], we obtained lipid 
raft (flotillin-labeled) and non-raft membrane prepara-
tions from control and treated cultures and tested them 
Fig. 1 Effects of BNP siRNA. a Representative immunocytochemical examples of endogenous BNP expression in mouse TG cultures in control 
(upper panels) and after BNP siRNA (lower panels). Nuclei are visualized with DAPI (blue); scale bar = 20 µm. b Representative current traces show 
α,β-meATP (10 µM, 2 s)-evoked P2X3 responses in control, after 48 h of siBNP, anantin application (500 nM, 2–3 h), or after a combination of siBNP 
treatment with application of anantin or BNP (100 ng/ml, 2–3 h). The scheme at the bottom describes aforementioned experimental protocols. His-
tograms show average P2X3 current density values (n = 33, 33, 40, 32, 33, respectively; *p < 0.05, Kruskal–Wallis test). Note that effects of BNP silenc-
ing and anantin application are not additive and statistically indistinguishable; BNP applied after siBNP depresses P2X3 currents to the control level
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with Western immunoblotting as exemplified in Fig. 4a. 
Hence, a significant increase in the amount of immu-
nopurified P2X3 receptors associated with the lipid raft 
compartment (R) vs the non-raft compartment (NR) was 
observed following 24 h anantin application (Fig. 4b, see 
examples in upper panel and data analysis at the bot-
tom; middle panels show total lysates; n =  4, p  <  0.05, 
Kruskal–Wallis test). It is noteworthy that, after anantin, 
there was no change in P2X3 receptor expression in total 
lysate samples that contained a broad assembly of mem-
brane and intracellular P2X3 receptors with different 
degree of maturation (lower panel in Fig. 4a; see also [9, 
12]). Consistent with previously reported data [34], the 
cholesterol-depleting agent MβCD (10 mM, 30 min treat-
ment) disrupted lipid rafts almost completely (see loss of 
flotillin labelling in Fig. 4a, upper panel) and shifted a sig-
nificant fraction of P2X3 receptors to the non-raft com-
partment, while the total amount of receptors remained 
constant (Fig.  4a, middle panel). Applying MβCD dur-
ing the last 30  min of anantin administration blocked 
the anantin effect on P2X3 membrane distribution: thus, 
most P2X3 receptors were redistributed from lipid rafts 
to the non-raft membrane compartment (Fig. 4a, exam-
ples in upper panels and data analysis at the bottom).
Forty-eight hours after siBNP, we observed effects sta-
tistically indistinguishable from those of anantin per se 
Fig. 2 Time-course of anantin effects on P2X3 receptor currents. a Histograms together with representative P2X3 currents induced by α,β-meATP 
(10 µM, 2 s) show time-course of anantin (500 nM) effects on P2X3 currents. Anantin significantly increases mean P2X3 current density values after 
1 h treatment already (n = 44, 30, 40, 40 for control, 1, 3 and 24 h treatment, respectively; *p < 0.05, Kruskal–Wallis test). b Representative traces 
obtained using α,β-meATP (10 µM, 2 s) show P2X3 current amplitudes in control, after 3 h anantin treatment (500 nM) and after 3 h anantin applica-
tion followed by 5 h wash with standard physiological solution. Histograms show average P2X3 current density values in control, anantin and wash 
out conditions (n = 42, 40, 33, respectively; *p < 0.05, Kruskal–Wallis test). Note that 5 h wash abolishes anantin effects on P2X3 current density. c 
Superimposed average traces of scaled P2X3 currents (shown as mean; sem is within the trace thickness), in control and after anantin treatment 
(n = 67, 76, respectively, Mann–Whitney rank sum test). Note no significant change in the current onset and slowing down of the decay after 
anantin application; τ1, τ2 are the fast and slow components of P2X3 current desensitization dynamics. Histograms show mean values for τ1 and τ2 
desensitization constants of P2X3 receptor currents in control and after 500 nM anantin application (n = 67, 76, respectively; *p < 0.05, Mann–Whit-
ney rank sum test)
Page 5 of 16Marchenkova et al. Mol Pain  (2015) 11:71 
in terms of localization of P2X3 receptors to the lipid 
raft membrane fraction (Fig. 4b, examples in upper pan-
els and data analysis at the bottom). This phenomenon 
was unchanged by adding anantin during the last 3 h of 
silencing, while there was no alteration in the total lysate 
expression of P2X3 receptor protein (Fig.  4b, middle 
panels).
Electrophysiological recordings of α,β-meATP (10 µM, 
2  s) induced P2X3 currents showed decreased peak 
amplitudes after MβCD treatment (p  <  0.05, Fig.  4c, 
right), similar to previous data [34]. Data from this set 
of experiments are presented as peak current amplitudes 
and not as current density values, since MβCD treatment 
affects cell capacitance by depleting the cholesterol con-
tent of the cell membrane and, thus, its dielectric com-
ponent (Fig. 4c, histograms on the left). After combined 
anantin and MβCD treatment, P2X3 current values were 
the same as in the control conditions (Fig.  4c, left and 
right). This result suggested that the combined adminis-
tration enabled potentiation by anantin despite MβCD 
even though it could not reach the level observed with 
anantin alone (Fig. 4c, left and right).
NPR‑A receptors modulate P2X3 serine phosphorylation
Previous reports have indicated that the efficiency of 
P2X3 receptors depends on their phosphorylation state, 
concerning in particular their serine or tyrosine resi-
dues [12, 13]. To look for mechanisms through which the 
BNP system may modulate P2X3 function, we checked 
if anantin affected P2X3 serine or tyrosine phosphoryla-
tion by screening immunoprecipitated membrane P2X3 
receptors with antibodies against the corresponding 
phosphorylated residues.
Figure  5a shows Western blot analysis of the serine 
phosphorylation (pSer) level in immunopurified mem-
brane P2X3 receptors in control or anantin-treated cul-
tures. The data revealed a significant reduction (n  =  4 
experiments, p < 0.05, Mann–Whitney rank sum test) of 
serine P2X3 phosphorylation (revealed as a single band; 
[13, 40]) following 1 h (Fig. 5a, examples in upper panels 
and data analysis on the right) or 24  h anantin applica-
tion (Fig. 5c, examples in upper panels and data analysis 
on the right), in analogy to the upregulation of P2X3 cur-
rents (Fig.  2a). By comparison, P2X3 tyrosine phospho-
rylation (pTyr) remained unaltered (Fig. 5b).
Silencing BNP for 48 h (with or without later applica-
tion of anantin) produced a reduction of P2X3 serine 
phosphorylation similar to the effect of anantin alone 
(Fig.  5d, examples in upper panels and data analysis on 
the right). Thus, inactivation of the NPR-A pathway by 
either blocking the receptors with anantin or exhaust-
ing cultures of endogenous BNP caused similar effects, 
confirming the idea of tonic regulation of P2X3 receptors 
activity by BNP via NPR-A.
Because calcineurin, CdK5, or CaMKII are known 
intracellular regulators of P2X3 receptor activity via 
changes in receptor phosphorylation [11, 13, 40, 41], we 
investigated whether blocking these enzymes might have 
effects analogous to those of anantin, and/or interact 
with the anantin potentiating action.
Figure  6a (left) shows mean values of P2X3 current 
density in cells treated for 30  min with the calcineu-
rin inhibitor FK-506 (5  µM), that increased P2X3 
currents without altering pSer P2X3, as previously 
Fig. 3 Anantin-mediated changes of P2X3 currents are not CGRP-
dependent. a Histogram shows mean current density values of P2X3 
receptors in control and after application of CGRP 8-37 (1 µM, over-
night), anantin (500 nM, 3 h), or their combination (n = 44, 40, 50, 43, 
respectively; *p < 0.05, Kruskal–Wallis test). Pretreatment with CGRP 
8-37 has no influence on anantin-mediated enhancement of P2X3 
current density values, suggesting that this effect is not mediated via 
CGRP release. Scheme on the right describes experimental protocol 
of anantin and CGRP 8-37 coapplication. b Histograms compare 
mean current density values of P2X3 receptors in control and after 
application of CGRP (1 µM, 3 h), anantin (500 nM, 2 h) or their combi-
nation (n = 42, 40, 34, 33, respectively; *p < 0.05, Kruskal–Wallis test). 
Adding CGRP to the anantin treatment does not further increase 
P2X3 currents. Scheme on the right describes experimental protocol 
of anantin and CGRP co-application
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reported [40]. Co-application of FK-506 together with 
anantin did not interfere with the effects of anan-
tin on P2X3 receptors (Fig.  6a, b). Although Cdk5 is 
a negative modulator of P2X3 receptor activity [13], 
unchanged effects of anantin were also observed 
when we used 48 h Cdk5 siRNA treatment (Fig. 6c, d). 
Likewise, while CaMKII is reported to control P2X3 
serine phosphorylation in TG neurons [40], the CaM-
KII antagonist KN-93 did not influence subsequent 
anantin effects on P2X3 receptors (Fig. 6e, f ). In sum-
mary, the basal Ser phosphorylation of P2X3 recep-
tors was under the distinct control of NPR-A receptors 
without apparently involving calcineurin, CdK5 or 
CaMKII.
Fig. 4 Anantin facilitates P2X3 localization to lipid rafts. a Top panel is a representative example of Western immunoblotting showing the amount of 
P2X3 receptors in raft (R) and non-raft (NR) membrane fractions in control and after treatment with anantin (500 nM, 24 h), MβCD (10 mM, 30 min) 
or their combination; flotillin bands indicate lipid raft membrane fractions. Lower panel shows total amount of P2X3 receptors for each experimental 
condition; β-tubulin was used as loading control of the total extract. Histograms at the bottom quantify mean P2X3 relative optical density values 
in lipid raft and non-raft membrane fractions (n = 4; *p < 0.05, Kruskal–Wallis test). Anantin relocates P2X3 receptors from non-raft to lipid raft 
membrane compartments, while MβCD abolishes anantin effect. b Top panel is a representative example of Western immunoblotting showing the 
amount of P2X3 receptors in raft and non-raft membrane fractions in control and after treatment with anantin (500 nM, 2–3 h), siRNA BNP (48 h), 
or their combination; flotillin bands indicate raft membrane fractions. Lower panel shows total amount of P2X3 receptors in each experimental 
condition; β-tubulin was used as loading control of the total extract. Histograms at the bottom quantify P2X3 relative optical density in lipid raft and 
non-raft membrane fractions according to the used treatment (n = 4; *p < 0.05, Kruskal–Wallis test). c Histograms show mean P2X3 current ampli-
tude values in control and after application of MβCD (10 mM, 30 min), anantin (500 nM, 2–3 h), or their combination (n = 47, 58, 40, 61; *p < 0.05, 
Kruskal–Wallis test). Representative current traces of P2X3 receptors evoked by α,β-meATP (10 µM, 2 s) for each experimental condition are shown 
on the right. MβCD per se decreases P2X3 current density, whereas MβCD co-application with anantin returns current density values to control level
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P2X3 serine phosphorylation and receptor membrane 
distribution
We next explored how the preferential lipid raft locali-
zation of P2X3 receptors and the decrease in P2X3 pSer 
were inter-related. Thus, we tested if lipid raft depletion 
with MβCD affected P2X3 pSer levels following anantin 
application.
Figure  7a shows a representative example of West-
ern blot analysis of P2X3 pSer levels in control or after 
application of anantin, MβCD or their combination. 
MβCD per se did not change basal P2X3 pSer level and 
did not influence the anantin-induced decrease in P2X3 
pSer (Fig. 7a, upper panels and diagram at the bottom). 
Furthermore, there was no significant difference in the 
level of pSer of P2X3 receptors between raft and non-
raft domains despite varying experimental conditions 
(Fig.  7b, upper panels and diagram at the bottom). 
Indeed, anantin produced an analogous two-fold reduc-
tion in P2X3 pSer in both compartments, regardless of 
the presence of MβCD.
Relying on these findings, it seems likely that P2X3 ser-
ine phosphorylation and receptor distribution between 
lipid rafts and non-raft membrane compartments were 
two separate processes targeted by the BNP/NPR-A 
pathway to regulate P2X3 receptor activity.
NPR‑A pathway is PKG dependent
Since NPR-A activation by BNP produces a rapid increase 
in cGMP level [25, 26, 42], one important downstream 
effector of this activity is the kinase PKG [9, 43–45]. We, 
therefore, inquired whether PKG might regulate P2X3 
pSer and/or receptor distribution at membrane level.
Fig. 5 Anantin increases P2X3 serine phosphorylation. a Western immunoblotting shows the amount of P2X3 pSer and total amount of P2X3 
receptors in control and after 1 h anantin (500 nM) application. β-tubulin was used as loading control of the total extract. Histograms on the right 
show statistically lower P2X3 pSer (relative optical density value) after anantin application compared to control (n = 4; *p < 0.05, Mann–Whitney 
rank sum test). b Representative example of Western immunoblotting, showing the amount of P2X3 pTyr and total amount of P2X3 receptors in 
control and after anantin application; β-tubulin used as loading control of the total extract. P2X3 pTyr does not change as shown in the plot on the 
right, summarizing pTyr P2X3 relative optical density in control and after anantin treatment. c Western immunoblotting shows the amount of P2X3 
pSer and total amount of P2X3 receptors in control and after prolonged anantin application (500 nM, 24 h) (n = 3; *p < 0.05, Mann–Whitney rank 
sum test). β-tubulin used as loading control of the total extract. Note that anantin effects after 24 h or 1 h of treatment (panels c and a, respec-
tively) are virtually indistinguishable. d Representative example of Western immunoblotting showing the amount of P2X3 pSer in control and after 
treatment with anantin (500 nM, 2–3 h), siRNA BNP (24 h), or their combination (n = 4); β-tubulin is used as loading control of the total extract. 
Histograms on the right quantify P2X3 pSer (relative optical density) according to the treatment (n = 4; *p < 0.05, Kruskal–Wallis test)
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Figure 8a shows that 2 h application of KT 5823 (1 µM), 
that is reported to be a selective PKG inhibitor at this 
concentration [46, 47], significantly increased control 
P2X3 current density values (Fig.  8a, middle and right), 
therefore mimicking the anantin action without any addi-
tive effect when co-applied with it. Likewise, KT 5823 
produced anantin-like effects on both P2X3 phosphoryl-
ation (Fig. 8b) and receptor distribution to raft/non raft 
membrane fractions (Fig.  8c), with no additivity when 
co-applied together with anantin. Hence, it is suggested 
that PKG, operating as an early gateway of the BNP/
NPR-A mediated molecular cascade, regulated P2X3 
Fig. 6 Anantin effects do not depend on the activity of CaMKII, Cdk5 kinase or the phosphatase calcineurin. a Bar plot summarizes means of 
P2X3 current density values in control and after application of calcineurin inhibitor FK-506 (5 µM, 2.5 h), anantin (500 nM, 2 h) or their combination 
(n = 37, 36, 40, 31, respectively; *p < 0.05, Kruskal–Wallis test). Scheme on the right describes experimental protocol of anantin and FK-506 coap-
plication. FK-506 pretreatment does not prevent anantin-induced increase of P2X3 current density values. b Representative example of Western 
immunoblotting (right) and the histogram (left), summarizing P2X3 pSer relative optical density values in control, after application of anantin 
(500 nM, 2 h), FK-506 (5 µM, 2.5 h), or their combination (n = 3; *p < 0.05, Kruskal–Wallis test). c Histograms show mean current density values 
of P2X3 receptors in control, after 24 h Cdk5 silencing with small interfering RNAs, after anantin application (500 nM, 3 h), or after a combination 
of those two treatments (n = 32, 31, 40, 30, respectively; *p < 0.05, Kruskal–Wallis test). Scheme on the right describes experimental protocol of 
combined siCdk5 and anantin treatments. Cdk5 RNA silencing does not prevent anantin from upregulating P2X3 receptor activity. d Representative 
example of Western immunoblotting (right) and histogram (left), summarizing P2X3 pSer (relative optical density values) in control, after applica-
tion of anantin, 24 h siCdk5, or a combination of these treatments (n = 3; *p < 0.05, Kruskal–Wallis test); β-tubulin used as loading control of the 
total extract. e Histograms compare mean current density values of P2X3 receptors in control and after application of CaMKII inhibitor KN-93 (5 µM, 
3.5 h), anantin (500 nM, 2 h), or their combination (n = 29, 26, 40, 28, respectively; *p < 0.05, Kruskal–Wallis test). Scheme on the right describes 
experimental protocol of anantin and KN-93 coapplication. KN-93 does not influence anantin-mediated increase in P2X3 current density. f Repre-
sentative example of Western immunoblotting (right) and histograms (left), summarizing P2X3 pSer (relative optical density values) in control and 
after application of anantin (500 nM, 2 h), KN-93 (5 µM, 3.5 h), or KN-93 together with anantin (n = 3; *p < 0.05, Kruskal–Wallis test)
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pSer and receptor distribution within the membrane 
compartments.
Discussion
The novel result of the present study is the demonstra-
tion that constitutive activation of NPR-A by endogenous 
BNP inhibited P2X3 receptor activity in mouse trigemi-
nal neurons. This process required two distinct modu-
latory mechanisms: P2X3 serine phosphorylation and 
receptor distribution to non-raft membrane compart-
ments. This is the first observation of an intrinsic process 
that may functionally restrain inappropriate activation of 
pain-sensing P2X3 receptors, and it raises the possibil-
ity that chronic pain, at least at the level of the trigeminal 
territory, might originate from dysfunction of endog-
enous negative regulators.
Negative control by BNP over P2X3 receptors
A difficulty in demonstrating this role of NPR-A recep-
tors (and of its ligand BNP) was the experimental need 
to block them to reveal their contribution to P2X3 recep-
tor activity. Thus, one important finding of the present 
work is that, once background BNP had been depleted by 
siRNA, we could demonstrate that exogenous BNP inhib-
ited P2X3 function. Because depletion of BNP by siRNA 
had a basal facilitatory effect on P2X3 receptors, we pro-
pose that NPR-A receptors needed background levels of 
BNP to exert their effect rather than being simply acti-
vated even in the absence of their natural ligand. Consist-
ent with that notion, the ambient concentration of BNP 
in TG cultures was rather low, yet clearly detectable even 
in the extracellular medium [26] and apparently sufficient 
to regulate P2X3 receptors. Furthermore, the effects of 
Fig. 7 P2X3 serine phosphorylation in raft and non-raft membrane compartments. a Top panel shows representative example of Western immuno-
blotting with P2X3 pSer and anti-P2X3 receptor antibodies, summarizing the amount of P2X3 receptors in control and after application of anantin 
(500 nM, 2–3 h), MβCD (10 mM, 30 min), or their combination. Lower panel shows total P2X3 receptor amount for each experimental condition; 
β-tubulin used as loading control of the total extract. Histograms at the bottom quantify P2X3 pSer (relative optical density values) for each experi-
mental condition (n = 4; *p < 0.05, Kruskal–Wallis test). Note that anantin effect on P2X3 pSer level is not influenced by MβCD. b Top panel shows 
representative example of Western immunoblotting with P2X3 pSer and P2X3 anti-P2X3 receptor antibodies, summarizing the amount of P2X3 
receptors in lipid raft (R) and non-raft (NR) membrane compartments in control and after application of anantin (500 nM, 2–3 h), MβCD (10 mM, 
30 min), or their combination. Lower panel shows total P2X3 receptor amount for each experimental condition; β-tubulin used as loading control of 
the total extract. Histograms at the bottom quantify the ratio between P2X3 pSer and total P2X3 in lipid raft and non-raft membrane fractions for 
each experimental condition (n = 4; *p < 0.05, Kruskal–Wallis test). Note that anantin reduces P2X3 pSer equally in both raft and non-raft mem-
brane fractions and this effect is not influenced by MβCD
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siBNP seem to suggest that BNP itself rather than other 
related natriuretic peptides was responsible for the modu-
lation of P2X3 receptors. Our interpretation is that, since 
basal levels of BNP constitutively depressed P2X3 recep-
tors, unmasking this phenomenon required blocking BNP 
or its receptor. The synthetic agonist α,β-meATP is selec-
tive for P2X3 receptor subunit and can, therefore, activate 
heteromeric P2X2/3 receptors as well [48–50] with their 
characteristic slow plateau current. While colocalization 
of P2X2 and P2X3 subunits has been previously reported 
in a number of mouse TG neurons, the contribution by 
P2X2/3 receptors to membrane currents is relatively small 
in view of the fact that slow-desensitizing responses are 
only detected in a minority of these cells [51]. Their small 
number precluded a systematic evaluation of BNP/NPR-A 
inhibition on heteromeric P2X2/3 receptors.
Fig. 8 Effects of the PKG inhibitor KT 5823. a Scheme on the left describes the protocol of anantin (500 nM, 2 h) and the selective PKG inhibitor KT 
5823 (1 µM, 2 h) co-application. Histograms (middle) show mean P2X3 current density values in control and after application of KT 5823 (1 µM, 2 h), 
anantin (500 nM, 2 h), or their combination (n = 33, 30, 40, 34, respectively; *p < 0.05, Kruskal–Wallis test). Representative current traces of P2X3 
receptors for each experimental condition are shown on the right and were evoked by 2 s pulses of 10 µM α,β-meATP. KT 5823 produces anantin-
like effect on P2X3 currents and shows no additivity when co-applied with anantin. b Representative example of Western immunoblotting with 
P2X3 pSer and P2X3 anti-P2X3 receptor antibodies (left) shows the amount of P2X3 receptors in control and after application of KT 5823 (1 µM, 
2 h), anantin (500 nM, 2 h) or their combination; histogram on the right quantifies P2X3 pSer (relative optical density values) for each experimental 
condition (n = 3; *p < 0.05, Kruskal–Wallis test). Note that KT 5823 is as efficient as anantin in lowering the amount of P2X3 pSer. c Representative 
example of Western immunoblotting (on the left) and the histograms (on the right) summarize the amount of P2X3 receptors and P2X3 pSer in lipid 
rafts and non-raft membrane fractions in control and after application of KT 5823 (1 µM, 2 h), anantin (500 nM, 2–3 h), or their combination (n = 3; 
*p < 0.05, Kruskal–Wallis test). KT 5823 acts like anantin, causing P2X3 receptors redistribution to the lipid raft membrane compartment
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The process responsible for the enhanced currents 
seen after suppressing the BNP/NPR-A system with 
either anantin or siBNP remains incompletely under-
stood. One contribution was likely to originate from 
the delayed onset of P2X3 receptor desensitization, an 
important parameter that controls current amplitude 
and pain signaling [15]. In the present work monitor-
ing the dynamics of the anantin action showed that 
BNP/NPR-A system regulated P2X3 receptors almost 
in all-or-none fashion because there was no gradual 
modulation of P2X3 currents: in fact, 30  min anan-
tin application was insufficient to affect P2X3 currents, 
whereas 1 h treatment produced P2X3 receptor upregu-
lation as strong as the one after 24  h, yet these effects 
were fully reversible on washout.
Because the effects of BNP/NPR-A system inactiva-
tion largely resembled the action of CGRP, a well-known 
positive P2X3 receptor modulator [9], we wondered if the 
BNP/NPR-A pathway might act by opposing the facili-
tatory role of CGRP [9, 35–38]. However, simultaneous 
block of NPR-A and CGRP receptors did not prevent full 
expression of the potentiating action by anantin, suggest-
ing independence of the BNP/NPR-A system from ambi-
ent CGRP.
BNP signaling relies on P2X3 receptor 
compartmentalization
Our former studies have reported higher peak ampli-
tudes and slower desensitization time of P2X3 recep-
tors when they are preferentially localized to lipid raft 
membrane compartments [34], a result similar to what 
we detected after anantin treatment. The lipid raft struc-
ture is highly mobile [52, 53], and potentially adaptable 
to accommodate redistribution of P2X3 receptors on 
the time scale seen after inactivation of the BNP/NPR-A 
system. In accordance with this notion, after anantin 
or siBNP, the number of P2X3 receptors localized to 
lipid raft membranes increased significantly without 
changes in the global receptor level, and this redistri-
bution was completely abolished by disrupting lipid 
rafts with MβCD. It is, however, noteworthy that, even 
after application of MβCD (that had made P2X3 cur-
rents smaller), anantin or siBNP could retain a moder-
ate degree of enhancing activity. Since the total number 
of P2X3 receptors had not changed, it is suggested that 
enhancement of P2X3 amplitudes could be partly, but 
not entirely, explained by the preferential P2X3 recep-
tors localization to lipid raft membrane fraction. This 
proposal implied the existence of an additional mecha-
nism, apart from receptor redistribution, employed 
by the BNP/NPR-A system to regulate P2X3 receptor 
function.
Changes in P2X3 phosphorylation state evoked by BNP/
NPR‑A block
As phosphorylation/dephosphorylation is one of the 
most common ways of altering receptor functions, for 
P2X3 receptors such a crucial regulatory role is often 
played by serine and tyrosine residues [5, 12, 13, 54, 55]. 
In our experiments anantin application or siBNP sig-
nificantly reduced the amount of P2X3 serine phospho-
rylation (with no change in tyrosine phosphorylation), a 
phenomenon shown before to associated to larger P2X3 
currents [13]. Disrupting lipid rafts with MβCD did not 
affect pSer or its decline after anantin application, sug-
gesting that membrane compartmentalization and recep-
tor phosphorylation were distinct phenomena.
Our working hypothesis is that there are two distinct 
branches of the BNP/NPR-A pathway targeting P2X3 
receptors. One regulates receptor distribution between 
lipid rafts and non-raft membrane compartments, the 
other one controls P2X3 serine phosphorylation level. 
Further investigations are required to unravel the details 
of the molecular cascade starting from NPR-A activation 
and resulting in depressed P2X3 currents.
Intracellular pathways linking NPR‑A receptors to P2X3 
receptors
In search for intermediate steps of the P2X3 modulating 
NPR-A pathway, we examined the involvement of kinases 
such as Cdk5 and CaMKII, and of the phosphatase cal-
cineurin, all previously shown to play a role in P2X3 
modulation [13, 40]. However, experiments with CaMKII 
or calcineurin antagonists, or siCdk5 indicated that these 
enzymes did not play a significant role in the NPR-A 
modulation of P2X3 pSer or current size.
Notwithstanding the elucidation of the intermediate 
factors controlling P2X3 receptors via NPR-A activity, 
our study examined the contribution by PKG as a down-
stream step after BNP/NPR-A activation. Our previous 
work has reported early changes in cGMP levels evoked 
by BNP [26] that would be expected to activate PKG, a 
family of intracellular kinases that regulate multiple 
intracellular targets [56–58]. Because KT 5823, used to 
inhibit PKG, mirrored the effects of anantin or siBNP, 
it seems that PKG activity was, indeed, a critical gate-
way to modulate P2X3 receptors. Using the ScanProsite 
tool (http://prosite.expasy.org/cgi-bin/prosite/ScanView.
cgi?scanfile=432156126103.scan.gz), we could not iden-
tify apparent consensus sites for the kinase activity on 
mouse P2X3 receptors. It appears, therefore, unlikely that 
PKG would directly phosphorylate discrete sites in the 
intracellular domains of the P2X3 receptors.
Figure  9 illustrates our proposal that the operation of 
P2X3 receptors under normal conditions is controlled 
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by the constitutively active NPR-A pathway due to ambi-
ent BNP. In our diagram, the basal level of BNP, which is 
partly produced in TG and mainly supplied to the tissue 
with the blood flow [24], constantly downregulates P2X3 
receptors, elevating their agonist threshold [26]. Hence, 
BNP via PKG activation mediated by NPR-A receptors 
would help to localize P2X3 receptors to non-lipid raft 
membrane compartments, to control their serine phos-
phorylation state, and to speed up their desensitization 
without impairing the ability to respond to the natural 
agonist ATP.
While our scheme includes a P2X3 inhibitory role of 
BNP via guanylate cyclase and cGMP production, any 
interaction between P2X3 receptors and other guanylate 
cyclase activators like nitric oxide (NO) remains unclear. 
NO donors such as glyceryl trinitrate (GTN) are used as 
models to induce trigeminal pain and delayed migraine 
[59]. Former studies show that GTN is effective only 
when given systemically [60] and that its migraine-pro-
voking activity is dependent on CGRP [61, 62]. This pro-
cess is, however, incompletely understood because CGRP 
antagonists do not block GTN headache [63]. Since acti-
vation of P2X3 receptors is known to trigger membrane 
translocation of the NO synthetic enzyme and NO pro-
duction [64], it is possible to speculate that P2X3 recep-
tor activity is an upstream event to NO-evoked cGMP 
synthesis and pain [65]. Thus, ongoing P2X3 inhibi-
tion by BNP via neuronal NPR-A receptors might be 
a primary mechanism for controlling the threshold to 
trigeminal nociception regulated by a complex mix of 
soluble factors.
The inhibitory role of the BNP/NPR-A system via PKG 
activity appears to be present also in DRG in which BNP 
(when co-applied with glutamate) depresses the excit-
ability of a subgroup of sensory neurons in a model of 
inflammatory pain [27]. In this study, BNP reduced the 
firing frequency of DRG neurons via intracellular signal-
ing leading to activation of large-conductance Ca2+-acti-
vated K+ channels (BKCa channels). Future investigations 
are necessary to explore whether P2X3 receptors, that are 
expressed by 40 % DRG neurons [66], are also a target for 
the inhibitory action by BNP.
Conclusions
In conclusion, the present data outline BNP as the first 
inhibitory neuropeptide to constitutively depress the 
P2X3 receptor function. The process appears to be 
NPR-A and PKG dependent and it involves P2X3 ser-
ine phosphorylation and receptor redistribution to the 
non-raft membrane compartments (Fig. 9). This sugges-
tion will have to be studied in the framework of complex 
mechanisms responsible for acute or chronic nociception 
at trigeminal sensory ganglion level. In particular, phar-
macological or genetic interference with the BNP/NPRA 
system in vivo and its effects on allodynia or hyperalge-
sia would significantly enhance the impact of the current 
results.
Methods
Animals and TG primary culture preparations
All animal procedures were conducted in accordance 
with the guidelines of the Italian Animal Welfare Act and 
regulations of animal welfare. All treatment protocols 
were approved by the Scuola Internazionale Superiore 
di Studi Avanzati (SISSA) ethics committee and are in 
accordance with the European Union guidelines. Trigem-
inal ganglion primary cultures were obtained from ani-
mals at the age of P12-14 as described previously [51] 
and employed after 24 or 48 h from plating.
Chemicals and treatments
A range of validated chemicals were used to uncover 
molecular mechanisms underlying the main biochemi-
cal and electrophysiological observations. The specific 
NPR-A receptor antagonist anantin (US Biologicals, 
Salem, MA, USA), the CGRP receptor antagonist CGRP 
8-37 (Sigma-Aldrich, Milan, Italy), and the cholesterol 
depleting agent methyl-β-cyclodextrin (MβCD, Sigma) 
were dissolved in sterile water and applied to the cell 
cultures medium. Anantin was applied for 30 min–24 h 
at the concentration of 500  nM to ensure full block of 
NPR-A receptors [26, 67]. CGRP 8–37 was applied in 
Fig. 9 The scheme of BNP/NPR-A dependent downregulation 
of P2X3 receptors. ATP (open circles, red) and BNP (filled circles) are 
extracellular ligands for P2X3 and NPR-A receptors, respectively. P2X3 
receptors are localized to lipid raft (R) and non-raft (NR) membrane 
compartments. When P2X3 receptors are in NR, they show less effi-
cient signaling. BNP by activating NPR-A receptors of sensory neurons 
activates guanylyn cyclase (GC) to increase intracellular cGMP and 
activate PKG. The latter indirectly regulates, in a negative fashion, 
P2X3 function by determining their localization to the non-raft 
domains and by facilitating their pSer
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1 μM concentration to effectively block CGRP receptors 
[39, 68–70]. MβCD (10 mM) was applied for 30 min in 
accordance with previous reports [34, 71, 72]. We also 
applied 5 μM FK-506 (dissolved in DMSO), a well-known 
immunosuppressant drug that induces persistent pain in 
humans [73, 74] and acts by inhibiting the Ca2+-depend-
ent phosphatase calcineurin [75]. KN-93 (5 μM) was used 
to block the activity of calcium calmodulin mediated 
kinase II (CaMKII) in accordance with previous studies 
[40]. KT 5823 (1 μM; Sigma) was used to inhibit PKG [46, 
47].
BNP and cyclin‑dependent kinase 5 (Cdk5) silencing
Cultured mouse trigeminal neurons were transfected 
with specific siRNA BNP (siBNP) oligonucleotides 
(Sigma), or siCdk5 oligonucleotide (ThermoFisher Sci-
entific, Milan, Italy) using the DharmaFECT transfec-
tion reagent (Dharmacon, Lafayette, CO, USA). As 
control (“scramble”), cells were transfected with siGLO 
RISC-Free siRNA (Dharmacon). The BNP siRNA and 
control siRNA were transfected at a final concentration 
of 100  nM for 24  h in triplicate for each treatment. At 
48  h post-transfection, BNP knockdown was confirmed 
by immunostaining and Elisa assay. A pool of two dif-
ferent oligonucleotide sequences were used to knock-
down BNP (NM_008726) expression, as previously 
published [76]: BNP siRNA-1: sense  5′-CCCAGAGAC 
AGCUCUUGAATT-3′ with antisense 5′-UUCAAGA 
GCUGUCUCUGGGTT-3′, and BNP siRNA-2: sense 
5′-GGCACAAGAUAGACCGGAUTT-3′ with anti-
sense 5′-AUCCGGUCUAUCUUGUGCCTT-3′. To 
knockdown Cdk5 expression (NM_007668.3), siCdk5 or 
control siRNA sequences were transfected at a final con-
centration of 100 nM. Twenty-four hours after silencing, 
cells were used for protein expression and patch clamp-
ing experiments. Efficiency of Cdk5 silencing was tested 
with Western blot.
Immunocytochemistry
Forty-eight hours after siRNA-treatment, primary cul-
tures from P12-P14 mouse TG were fixed in 4  % para-
formaldehyde and immunofluorescence was carried 
out as previously described [26]. Polyclonal antibody 
against BNP (G-011-23; 1:100) was from Phoenix Phar-
maceuticals (Burlingame, CA, USA). Secondary antibody 
conjugated with Alexa Fluor-594 was purchased from 
Invitrogen (1:500; Milan, Italy). Nuclei were counter-
stained with DAPI (Sigma). Images were obtained using a 
Leica TCS SP2 confocal microscope (Wetzlar, Germany).
Membrane fractionation and protein extraction
Total membrane protein extraction and Triton X-100-sol-
uble and -insoluble fractionation were performed as 
reported by Gnanasekaran et  al. 2011 [34]. To ensure 
equal loading for each cell lysate, protein extracts were 
quantified with bicinchoninic acid (BCA; Sigma). The 
amount of loaded proteins was in the 20–50 µg/ml range. 
Immunoprecipitation of P2X3 receptors from membrane 
fractions (raft and non-raft) was performed as previously 
reported [12].
Western blot
Western blot analysis was performed according to the 
methods previously reported [12, 26]. Cells were lysed in 
ODG buffer solution (2  % n-octyl-beta-d-glucopyrano-
side, containing 1  % Nonidet P-40, 10  mM Tris pH 7.5, 
150  mM NaCl, plus protease inhibitors mixture; Com-
plete, Roche Applied Science, Basel, Switzerland). Pro-
teins were separated in 10  % SDS–polyacrylamide gel 
and transferred to nitrocellulose membranes. Immuno-
blotting was performed with the following validated pri-
mary antibodies: rabbit anti-P2X3 (1:1000; Santa Cruz 
Biotechnology, Heidelberg, Germany) rabbit anti-NPR-
A (1:1000, Abcam), anti-β-tubulin III (1:2000; Sigma), 
mouse anti-β-actin (1:3000, Sigma), mouse anti-flotillin 
1 (1:250; BD Biosciences), anti-phospho-Serine (1:500, 
millipore), anti-phospho-Tyrosine (1:500, millipore) 
[26, 34, 40]. Signals were revealed after incubation with 
recommended secondary antibodies conjugated with 
horseradish peroxidase by using ECL detection rea-
gent (Amersham Biosciences, Piscataway, NJ, USA) 
and recorded by the digital imaging system Alliance 4.7 
(UVITEC, Cambridge, UK).
ELISA assay for BNP
Samples from TG cultures and their culture medium 
were collected 24  h after plating and prepared as 
described by Vilotti et  al. (2013). The BNP levels were 
assessed using an ELISA kit (Abnova, Hidelberg, Ger-
many), following the instructions of the manufacturer. 
Sample BNP levels were determined using standard con-
centration curves and evaluated in duplicate. Data were 
normalized to sample protein concentration, as deter-
mined by the BCA method (Sigma).
Electrophysiology
Electrophysiology experiments were performed using 
previously reported protocols [39, 51]. Cultured TG 
neurons were patch-clamped in the whole-cell con-
figuration under continuous perfusion (3 mL/min) with 
physiological solution containing (in mM): 152 NaCl, 
5 KCl, 1 MgCl2, 2 CaCl2, 10 glucose, and 10 HEPES (pH 
adjusted to 7.4 with NaOH). Patch pipettes were filled 
with the following solution (in mM): 140 KCl, 0.5 CaCl2, 
2 MgCl2, 2 Mg2ATP3, 2 GTP, 10 HEPES and 10 EGTA 
(pH adjusted to 7.2 with KOH) and had a resistance of 
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3–4  MΩ. Recordings were performed from small and 
medium size trigeminal neurons [39] held at −65  mV 
after correction for liquid junction potential. Currents 
were filtered at 1 kHz and acquired by means of a Digi-
Data 1200 interface and pClamp8.2  software (Molecu-
lar Devices, Sunnyvale, CA, USA). In accordance with 
our previous studies α,β-methylene-adenosine-5′-
triphosphate (α,β-meATP; Sigma), a stable synthetic 
agonist of P2X3 receptors [33] was applied for 2 s at a 
standard dose of 10 µM [26, 33, 39] using a fast superfu-
sion system (Rapid Solution Changer RSC-200; BioLogic 
Science Instruments, Claix, France) to evoke reproduc-
ible near-maximal P2X3 responses [13, 77]. Data were 
collected from at least 4 individual experiments with 
number of cells equal or greater than 25. Responses were 
measured as peak amplitudes and presented as current 
density values (pA/pF) after normalization to the cells’ 
capacity, in order to eliminate differences in currents 
originated from cell size variation. The only exception 
were experiments with MβCD, where the data were 
shown as peak current amplitudes, since MβCD, as a 
cholesterol depleting agent, is expected to change cell 
capacitance.
Statistical analysis
Data are expressed as mean ±  standard deviation (s.d.) 
or as mean ± standard error of the mean (SEM), where n 
indicates the number of independent experiments or the 
number of investigated cells, as indicated in figure leg-
ends. Statistical analysis was performed using nonpara-
metric Mann–Whitney rank sum test, or the Student’s t 
test, after the software-directed choice of non-parametric 
or parametric data, respectively (Matlab; Sigma Plot and 
Sigma Stat Software, Chicago, IL, USA), or Kruskal–
Wallis test for multiple comparison. A p value of <0.05 
was accepted as indicative of a statistically significant 
difference.
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